De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study

Organ transplant recipients appear to have a higher risk of de novo malignancy. The aim of the study was designed to estimate cancer risk in heart, lung, kidney and liver transplant recipients. The cohort study used the Taiwan National Health Insurance Research Database (1996-2011) and followed the outcomes of organ recipients until 2012. De novo cancer and mortality rates after organ transplantation were evaluated using standardized incidence ratios, excess absolute risks of cancer, and standardized mortality ratios in recipients were compared with those in the general population. We identified 40, 231, 2, and 115 patients who developed cancer after heart, kidney, lung, and liver transplantation, which corresponded to a cancer incidence of 878.4, 1101.2, 728.9, and 1361.4 cases per 100,000 person-years, respectively. In heart, kidney, lung, and liver recipients, the overall standardized incidence ratios were 1.65 (1.21-2.24), 3.33 (2.93-3.79), 1.82 (0.45-7.27) and 3.37 (2.81-4.05) and the overall standardized mortality ratios were 5.45 (4.96-5.98), 1.47 (1.34-1.61), 8.92 (7.10-11.20), and 3.83 (3.48-4.20), respectively. These results reveal a three-fold increase in de novo cancer risk in organ transplant patients compared with the general population. This study illustrated the importance of de novo malignancy after organ transplantation.

[1]  H. Date,et al.  De novo malignancy after lung transplantation in Japan , 2016, General Thoracic and Cardiovascular Surgery.

[2]  S. Kim,et al.  Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. , 2016, JAMA oncology.

[3]  H. Date,et al.  Malignancies after living-donor and cadaveric lung transplantations in Japanese patients , 2016, Surgery Today.

[4]  L. Holmberg,et al.  Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation – experiences from a prospective, clinical, observational study , 2016, Acta oncologica.

[5]  A. Grulich,et al.  The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. , 2015, Seminars in oncology.

[6]  J. Hercogová,et al.  Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic. , 2015, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[7]  D. Serraino,et al.  Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors. , 2014, Best practice & research. Clinical obstetrics & gynaecology.

[8]  K. McGlynn,et al.  Risk of hepatobiliary cancer after solid organ transplant in the United States. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  R. Pfeiffer,et al.  Cumulative incidence of cancer after solid organ transplantation , 2013, Cancer.

[10]  A. Keogh,et al.  De novo Cancer‐Related Death in Australian Liver and Cardiothoracic Transplant Recipients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  G. Edgren,et al.  Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—A Swedish population‐based study , 2013, International journal of cancer.

[12]  D. Segev,et al.  Racial/Ethnic Differences in Cancer Risk After Kidney Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  A. Keogh,et al.  Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  K. Lamb,et al.  Associations Between EBV Serostatus and Organ Transplant Type in PTLD Risk: An Analysis of the SRTR National Registry Data in the United States , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  H. Saconato,et al.  Comparative incidence of cancer in HIV-AIDS patients and transplant recipients. , 2012, Cancer epidemiology.

[16]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[17]  Y. Pawitan,et al.  Time Trends in Risk and Risk Determinants of Non‐Hodgkin Lymphoma in Solid Organ Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  Fiona O'Reilly Zwald,et al.  Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. , 2011, Journal of the American Academy of Dermatology.

[19]  K. Chan,et al.  Renal cell carcinoma of native kidney in Chinese renal transplant recipients: a report of 12 cases and a review of the literature , 2011, International Urology and Nephrology.

[20]  E. Engels,et al.  Hodgkin Lymphoma Among US Solid Organ Transplant Recipients , 2010, Transplantation.

[21]  J. Neuberger,et al.  Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  P. Villeneuve,et al.  The Incidence of Cancer in a Population‐Based Cohort of Canadian Heart Transplant Recipients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  G. Opelz,et al.  Epidemiology of Pretransplant EBV and CMV Serostatus in Relation to Posttransplant Non-Hodgkin Lymphoma , 2009, Transplantation.

[24]  C. Vajdic,et al.  Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.

[25]  P. Mazzone,et al.  Bronchogenic Carcinoma after Lung Transplantation: Characteristics and Outcomes , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  R. Sankila,et al.  Risk of malignant neoplasms after liver transplantation: A population‐based study , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[27]  C. Lebbé,et al.  Kaposi sarcoma in transplantation. , 2008, Transplantation reviews.

[28]  E. Engels.  Inflammation in the development of lung cancer: epidemiological evidence , 2008, Expert review of anticancer therapy.

[29]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[30]  P. Villeneuve,et al.  Cancer Incidence Among Canadian Kidney Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  S. Franceschi,et al.  Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients , 2005, British Journal of Cancer.

[32]  H. Adami,et al.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden , 2003, British Journal of Cancer.

[33]  D. Hébert,et al.  Lymphoproliferative disorders after organ transplantation in children. , 1999, Transplantation.

[34]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.